BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Cancer: Finding New Targets and Novel Therapies - Dr Molly Taylor 
 (Astra Zeneca)\, Dr Chiranjeevi Sandi (Astra Zeneca) &amp\; Dr James Lynch
  (Astra Zeneca) 
DTSTART:20160608T173000Z
DTEND:20160608T190000Z
UID:TALK66322@talks.cam.ac.uk
CONTACT:Mark Dunning
DESCRIPTION:Non-small cell lung cancer is the leading cause of cancer deat
 h worldwide. Analysis of microRNA expression data from The Cancer Genome A
 tlas (TCGA) and cell line samples can be used to identify differentially e
 xpressed microRNAs. These may function as biomarkers and\naid to predict r
 esponse to therapy.\n\nProstate cancer is the second most common cancer an
 d fifth leading cause of cancer-related\nmortality in men. Forty percent o
 f primary prostate and 100% metastatic prostate tumours\nhave activated PI
 3K/AKT/mTOR signalling pathway. First generation mTOR inhibitors only\ninh
 ibit mTORC1 but spare mTORC2. How would a dual mTOR inhibitor work?\n\nNew
  targets for new drugs: To identify tumour types with a potential to be se
 nsitive to PI3K\npathway inhibitors\, which are currently in clinical tria
 ls\, four compounds were screened\nagainst the Sanger cancer cell line pan
 el. A strong correlation with sensitivity in haematological\nmalignancies 
 was observed\, identifying potential novel disease segments amenable to PI
 3K\npathway inhibition.\n
LOCATION:Postdoc Centre\, 16 Mill Lane
END:VEVENT
END:VCALENDAR